1935Dr K A Hamied sets up "The Chemical, Industrial and PharmaceuticalLaboratories Ltd." in a rented bungalow, at Bombay Central.1941As the Second World War cuts off drug supplies, the company startsproducing fine chemicals, dedicating all its facilities for the war effort.1952Sets up first research division for attaining self-sufficiency in technologicaldevelopment.1960Starts operations at second plant at Vikhroli, Mumbai, producing finechemicals with special emphasis on natural products.1968Cipla manufactures ampicillin for the first time in the country.
1972Starts Agricultural Research Division at Bangalore, for scientific cultivationof medicinal plants.1976Cipla launches medicinal aerosols for asthama.1980Wins Chemexcil Award for Excellence for exports.1982Fourth factory begins operations at Patalganga, Maharashtra.1984Develops anti-cancer drugs, vinblastine and vincristine in collaboration withthe National Chemical Laboratory, Pune. Wins Sir P C Ray Award fordeveloping inhouse technology for indigenous manufacture of a number ofbasic drugs.
Milestones1985US FDA approves Ciplas bulk drug manufacturing facilities.1988Cipla wins National Award for Successful Commercialization of PubliclyFunded R&D.1991Launches etoposide, a breakthrough in cancer chemotherapy, in associationwith Indian Institute of Chemical Technology.The company pioneers themanufacture of the antiretroviral drug, zidovudine, in technologicalcollaboration with Indian Institute of Chemical Technology, Hyderabad.
1999Launches Nevirapine, antiretroviral drug, used to prevent the transmissionof AIDS from mother to child.2000Cipla became the first company, outside the USA and Europe to launchCFC-free inhalers – ten years before the deadline to phase out use of CFCin medicinal products.2002Four state-of-the-art manufacturing facilities set up in Goa in a record timeof less than twelve months.
1994Ciplas fifth factory begins commercial production at Kurkumbh,Maharashtra.1997Launches transparent Rotahaler, the worlds first such dry powder inhalerdevice now patented by Cipla in India and abroad. The palliative cancercare centre set up by the Cipla Foundation, begins offering free services atWarje, near Pune.1998Launches lamivudine, becoming one of the few companies in the world tooffer all three component drugs of retroviral combination therapy(zidovudine and stavudine already launched).
2003Launches TIOVA (Tiotropium bromide), a novel inhaled, long-actinganticholinergic bronchodilator that is employed as a once-dailymaintenance treatment for patients with chronic obstructive pulmonarydisease (COPD).Commissioned second phase of manufacturing operationsat Goa.2005Set-up state-of-the-art facility for manufacture of formulations at Baddi,Himachal Pradesh.2007Set-up state-of-the-art facility for manufacture of formulations at Sikkim.
To build a healthy India. And along the way realized , that in our own small way ,we could Contribute to making the world a healthier place. We will continue tobring a smile on as many faces as we can to heal the world as much as we can.VISION
At Cipla we enjoy challenges and creating changefor the better – for patients and doctors, and forour own people. Some of our most successfulmanagers are in their 20s and 30s, and still risingbecause they work with energy and passion. If youare looking for a mission for life, look up ourCareers section
“Cipla commits itself to endeavor to satisfy our customers needsin every manner possible: through excellent service, bydeveloping and marketing an effective, safe, quality product andby offering our product at a price affordable to all patients” “It is our wish that we be recognized as innovators in the field ofpharmaceutical marketing rather than just followers, be theinvestors pick and achieve sustainable above average returns tothe investor”.“It is our dream that through our policy of dedication andcommitment we will create an environment whereby Cipla willcome to be recognized as the preferred partner in medicine”.
CIPLA RESEARCH & DEVELOPMENTWhile our skills are among the best in the world, what makesus different is our multi-disciplinary approach to research.We believe there’s no use in developing life-saving medicinesif we can’t make them affordable for the patient.Cipla opened the doors of hope to millions and millions ofpatients by becoming the first company in the world to offerthe Triple-Drug AIDS Cocktail for less than a dollar a day. Oneout of every three HIV-AIDS patients under treatment in Africauses a Cipla drug..
2oo8- Active in overseas markets. Cipla pips Ranbaxy. Gets Thumbs up for Generic HIV Drug. 2009- retail market grows 15% Gets Tentative USFDA Approval Pharmaceuticals Export Promotion Council Awards Launches generic drug to treat H1N1 2010-piramal healthcare acquires “i-pill” ,a leadingEmergency contraceptive brand from Cipla Extends an innovative “Mother-Baby Pack” for preventingmother-to-child transmission of HIV
The company posted a net profit of Rs 767 crore for the year ended March 31, 2009,as compared to Rs 701 crore in the corresponding period last year. Total incomeincreased from Rs 4,271 crore for the year ended March 31, 2008 to Rs 5,338 crore forthe year ended March 31, 2009.
1. Ethical conductAll directors and senior management employees shall deal on behalf of thecompany with professionalism, honesty, integrity as well as high moraland ethical standards. Such conduct shall be fair and transparent and beperceived to be as such by third parties.2. Conflict of interestAny director or senior management employee of the Company shall notengage in any business, relationship or activity, which might detrimentallyconflict with the interest of the Company.Code of conduct
3. TransparencyAll directors and senior management employees of the Company shallensure that their actions in the conduct of business are totally transparentexcept where the needs of business security dictate otherwise. Suchtransparency shall be brought about through appropriate policies, systemsand processes.4. Legal complianceAll directors and senior management employees of the Company shall at alltimes ensure compliance with all the relevant laws and regulationsaffecting operations of the Company.
5. Rightful use of company’s assetsAll the assets of the Company both tangible and intangible shall beemployed for the purpose of conducting the business for which they areduly authorized.6. Cost consciousnessAll the directors and senior management employees of the Companyshould strive for optimum utilization of available resources. They shallexercise care to ensure that costs are reasonable and there is no wastage.
7. Confidential informationAll directors and senior management employees shall ensure that anyconfidential information gained in their official capacity is not utilized forpersonal profit or for the advantage of any other person. They shall notprovide any information either formally or informally to the press or to anyother publicity media unless specifically authorized to do so.8. Relationships with Suppliers and CustomersThe Directors and senior management employees of the Company duringthe course of interaction with suppliers and customers, shall neitherreceive nor offer or make, directly and indirectly, any illegal payments,remuneration, gifts, donations or comparable benefits which are intendedor perceived to obtain business or uncompetitive favours for the conduct ofits business. However this is not intended to include gifts of customarynature.
9. Interaction with MediaThe Directors and senior management employees other than thedesignated spokespersons shall not engage with any member of press andmedia in matters concerning the Company. In such cases, they shoulddirect the request to the designated spokespersons.10. Safety and EnvironmentThe Director and senior management employees shall follow all prescribed safety andenvironmental related norms.
World Health Organization Food and Drug Administration (FDA), USA Therapeutic Goods Administration (TGA), Australia Pharmaceutical Inspection Convention (PIC),Germany National Institute of Pharmacy (NIP), Hungary The Medicines and Healthcare products RegulatoryAgency (MHRA) is the UK government agency